| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.58B | 51.67B | 47.57B | 44.47B | 40.69B | 37.78B |
| Gross Profit | 48.58B | 47.91B | 44.30B | 42.01B | 40.30B | 37.34B |
| EBITDA | 7.80B | 11.71B | 8.70B | 8.41B | 7.66B | 4.93B |
| Net Income | 6.26B | 7.50B | 6.22B | 5.49B | 4.08B | 2.46B |
Balance Sheet | ||||||
| Total Assets | 3.26T | 3.18T | 3.16T | 3.01T | 3.16T | 3.05T |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 270.96B | 201.84B | 72.97B | 301.83B | 377.50B |
| Total Debt | 42.38B | 45.20B | 57.33B | 72.13B | 208.39B | 168.55B |
| Total Liabilities | 3.14T | 3.06T | 3.04T | 2.90T | 3.05T | 2.92T |
| Stockholders Equity | 119.52B | 116.37B | 122.56B | 108.76B | 115.78B | 126.41B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 20.36B | -26.20B | -190.17B | -4.59B | 230.85B |
| Operating Cash Flow | 0.00 | 22.94B | -24.61B | -188.82B | -3.58B | 6.54B |
| Investing Cash Flow | 0.00 | 95.41B | 14.54B | -43.72B | -67.45B | -67.86B |
| Financing Cash Flow | 0.00 | 18.00B | 143.86B | -1.18B | 86.57B | 324.17B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥88.83B | 1.54 | ― | 3.05% | 8.75% | -12.68% | |
71 Outperform | ¥80.67B | 5.15 | ― | 2.49% | 7.08% | -46.44% | |
69 Neutral | ¥80.71B | 10.96 | ― | 2.89% | -0.24% | 95.49% | |
69 Neutral | ¥69.35B | 6.31 | ― | 2.34% | -0.97% | 27.62% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
66 Neutral | ¥74.50B | 7.94 | ― | 2.29% | 7.97% | 20.44% | |
52 Neutral | ¥97.56B | 6.95 | ― | 2.12% | 10.91% | -1225.48% |
The Bank of Saga Ltd. has sold all 2,356,000 common shares it held in Hisamitsu Pharmaceutical Co., Inc. into a tender offer conducted by TAIYO KOSAN CO., INC., at a price of ¥6,082 per share. The transaction, to be settled on February 27, 2026, results in a total sale amount of ¥14,329 million and a gain on sale of ¥12,048 million, eliminating the bank’s equity stake in Hisamitsu.
As a result of this divestment, the Bank of Saga plans to record a significant gain on sale of equity securities on a consolidated basis in the fiscal year ending March 31, 2026. The bank is currently reviewing its consolidated earnings forecasts for that fiscal year in light of the tender offer proceeds and other factors, indicating potential revisions that may affect shareholder expectations and financial performance indicators once finalized.
The most recent analyst rating on (JP:8395) stock is a Buy with a Yen5286.00 price target. To see the full list of analyst forecasts on Bank of Saga Ltd. stock, see the JP:8395 Stock Forecast page.
The Bank of Saga reported consolidated ordinary income of ¥44.2 billion for the nine months ended December 31, 2025, up 3.9% year on year, with ordinary profit rising 13.6% to ¥10.0 billion. Profit attributable to owners of parent climbed 16.4% to ¥7.2 billion, lifting basic earnings per share to ¥424.70 and supporting a modest improvement in the equity-to-asset ratio to 3.9% as total assets stood at ¥3.14 trillion.
The bank plans to pay a total annual dividend of ¥100 per share for the fiscal year ending March 31, 2026, an increase from ¥90 in the previous year, signaling confidence in earnings sustainability. Management left its full-year forecast unchanged, projecting ¥56.0 billion in ordinary income and ¥8.0 billion in profit attributable to owners, suggesting stable but moderate growth expectations for shareholders and other stakeholders.
The most recent analyst rating on (JP:8395) stock is a Buy with a Yen5286.00 price target. To see the full list of analyst forecasts on Bank of Saga Ltd. stock, see the JP:8395 Stock Forecast page.